#Acarix @acarixtweet
The exposure Acarix is receiving in the USA is unparalleled! Despite being a relatively unknown entity in Sweden, this small company is at the forefront of a comprehensive USA launch of the CADScorยฎ System, a point-of-care diagnostic aid utilizing highly sensitive acoustics and AI to exclude coronary artery diseases. In less than 6 months, the company has transitioned from 0% to 30% American ownership, with 20% secured through a targeted issuance and the remainder through the OTC market.
Acarix has also appointed a high-profile CEO based in the USA and expanded its Advisory Board with three new advisors, all prominent figures in the fields of cardiology and medtech industry in USA. Within 2-4 weeks, Acarix will also be dual-listed on OTCQB. The exposure leading up to the USA listing for Acarix is extraordinary! Just in the past few days, the following developments have occurred ๐๐ผ